Malignant pleural mesothelioma (MPM), which is associated with exposure to asbestos fibers, is an aggressive neoplasm that develops in the pleura, and is highly invasive to surrounding tissues. [1] [2] [3] In particular, MPM has been shown to be resistant to all conventional therapies, including chemotherapy, radiotherapy and surgery, leading to a very poor prognosis of MPM patients. Consequently, it is a tumor that continues to be a difficult clinical problem. 1-3 Therefore, development of novel therapeutic agents against MPM is highly desirable.
Chemical Industries), 0.0005% ZnSO 4 Á 7H 2 O (Wako Pure Chemical Industries) and 0.0005% MnCl 2 Á 4H 2 O (Junsei Chemical). The flasks were placed on a rotary shaker (220 r.p.m.) at 28 1C and incubated for 3 days. Measured aliquots (0.5 ml) of the broth were then transferred to 500-ml Erlenmeyer flasks containing 50 ml of production medium of the same composition, and were cultured on a rotary shaker (220 r.p.m.) at 28 1C for 4 days. The whole culture broth (2 l) was then extracted with n-butanol (2 l).
After concentrating the extract in vacuo, the residual aqueous concentrate (15.8 g) was extracted with ethyl acetate (EtOAc) (100 ml Â 3). The separated organic layer was dried over Na 2 SO 4 and concentrated in vacuo. The dried residue (1.16 g) was subjected to normal-phase medium-pressure liquid chromatography (Purif-Pack SI-30; Shoko Scientific, Yokohama, Japan), and was eluted stepwise by using a hexane-EtOAc solvent system (0, 5, 10, 20 and 25% EtOAc) followed by a CHCl 3 ÀMeOH solvent system (0, 2, 5, 10 and 20% MeOH). The active eluate (5% MeOH, 380 mg) was subjected to reversed-phase medium-pressure liquid chromatography (Purif-Pack ODS-100), and was eluted stepwise by using a H 2 O-MeOH solvent system (40, 60, 80 and 100% MeOH). The active eluate (80% MeOH, 79 mg) was further purified by preparative reversed-phase HPLC by means of a Capcell Pak C 18 MGII column (5.0 mm, 20 i.d. Â 150 mm; Shiseido, Tokyo, Japan) with a Model 2996 photodiode array detector (Waters, Milford, MA, USA) and a Model 3100 mass detector (Waters), eluting with 75% aqueous MeOH containing 0.1% formic acid (flow rate, 10 ml min À1 ) to yield compound 1 (2.4 mg, retention time 37.9 min). Table 1 . The structure elucidation of compound 1 by means of DQF-COSY and constant time-HMBC 8 spectra is described in the following section.
Three substructures were recognized by analyzing DQF-COSY and CT-HMBC. The 1 H-1 H spin correlation was observed between doublet olefinic protons H-2 (d H 6.03) and H-3 (d H 7.10). In the CT-HMBC spectrum, 1 H-13 C long-range couplings were observed from the olefinic protons H-2 and H-3 to a carboxylic carbon C-1 (d C 170.6) and a quaternary olefinic carbon C-4 (d C 151.7), which in turn coupled to a methoxy proton 4-OCH 3 Figure 1b . In addition, treatment with TMS-diazomethane resulted in the production of a 1-COOMe derivative, which also confirms that C-1 consists of a carboxylic acid group. The configurations of the triene side chain moiety in compound 1 were established to be 2E, 4Z and 6E by the means of analyzing the proton spin-coupling constant between H-2 and H-3 (J ¼ 15.5 Hz), and the strong NOESY correlations between H-3/H5 (2E), H-5/H-7 (4Z) and 4-OMe/6-Me (6E). We observed that the high-field-shifted 13 C chemical shift value at 6-Me (d C 14.9) due to the g-effect also supported the stereochemistry at C-6. Thus, the planar structure of compound 1 was determined as shown in Figure 1a .
The cytotoxic effects of compound 1 against various MPM cell lines were determined by a colorimetric assay with 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt (WST-8, Cell Counting Kit; Dojindo, Kumamoto, Japan) for 48 h. Compound 1 exhibited cytotoxic activities against three MPM cell lines, Meso-1, Meso-8A and Meso-8D with IC 50 values of 32, 40 and 78 mM, respectively. These cytotoxic effects were similar to those of JBIR-23 (IC 50 values of 31, 39 and 111 mM, respectively). As compound 1 showed considerable effects on the MPM cell lines that demonstrate resistance to clinical anticancer drugs, it is expected to be an invaluable lead compound for developing anti-MPM drugs.
The structure of compound 1 differs from that reported for cuevaene A in the substitution position of the side chain on the tricyclic ring system of cuevaene A (corresponding to C-11 position in compound 1). Cuevaene A, which displayed moderate antibacterial activity against Gram-positive bacteria, was isolated from Streptomyces sp. HKI 0180. 6 We have reported two structurally related compounds, named JBIR-23 and -24, isolated from the same species, which showed moderate cytotoxic effects against several MPM cell lines. 4, 5 All of these natural products embrace the tricyclic core and the triene side chain with an enol methyl ether. Although the structure of cuevaene A was originally proposed as shown in Figure 1a , we suggest that it is revised to that of compound 1 by altering the connective position of the triene side chain to the same site on the cyclohexane ring as that in JBIR-23 and -24, based on the extensive NMR correlations and the possible biosynthetic relationship among the compounds.
Recently, Liu et al. 9 reported the syntheses of these two structures. The NMR spectra of the synthetic isomers are very similar to each other, and the published data for original cuevaene A do not match either isomer very well. On the other hand, Taylor et al. 10 have just reported the total synthesis of cuevaene A with alternative structure. The NMR spectroscopic data of synthesized cuevaene A with revised structure corresponded with those of compound 1. Therefore, we revised the structure of cuevaene A as compound 1.
From a biosynthetic point of view, the structure of compound 1 seems to be quite plausible, because it presumably arises through the polyketide pathway utilizing a benzoic acid as a starter unit, in which the side chain moiety is substituted at the same position corresponding to JBIR-23 and JBIR-24. Studies on detailed biological activities including the mechanism of action and the biosynthesis of compound 1 are now under way.
